Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: FEC Chemotherapy|PROCEDURE: Surgery|DRUG: Docetaxel|DRUG: Pertuzumab|DRUG: Placebo|DRUG: Trastuzumab
Sponsor: Hoffmann-La Roche